Which cephalosporin for gonorrhoea?

Sexually Transmitted Infections

Volumn 80, Issue 5, 2004, Pages 386-388

  Ison, Catherine A ^a   Mouton, J W ^b   Jones, K ^c   Fenton, K A ^a   Livermore, D M ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b CANISIUS WILHELMINA HOSPITAL   (Netherlands)

^c Center for Sexual and HIV Research   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMPICILLIN; ANTIINFECTIVE AGENT; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE; CEFIXIME; CEFTRIAXONE; CEFUROXIME; CEFUROXIME AXETIL; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; MACROLIDE; PENICILLIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPECTINOMYCIN; TETRACYCLINE DERIVATIVE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL STRAIN; BACTERIUM ISOLATE; CLINICAL PROTOCOL; DISTRIBUTION VOLUME; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CHOICE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDICATION; DRUG POTENCY; DRUG UTILIZATION; FEMALE; GONORRHEA; HUMAN; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; NEISSERIA GONORRHOEAE; NONHUMAN; PHARMACODYNAMICS; PHARMACOKINETICS; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; UNITED KINGDOM; ARTICLE; MICROBIOLOGICAL EXAMINATION; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; GONORRHEA; HUMANS; MICROBIAL SENSITIVITY TESTS; TREATMENT OUTCOME;

EID: 6044235659     PISSN: 13684973     EISSN: None     Source Type: Journal    
DOI: 10.1136/sti.2004.012757     Document Type: Review

References (22)

1. Fenton KA, Ison C, Johnson AP, et al. Ciprofloxacin resistance in Neisseria gonorrhoeae in England and Wales in 2002. Lancet 2003;361:1867-9.
2. Ross JD, Maw R. How is gonorrhoea treated in genitourinary medicine clinics in the UK? Int J STD AIDS 2002;13:499-500.
3. GRASP Steering Group. The gonococcal resistance to antimicrobial surveillance programme. London: Health Protection Agency, 2003.
4. Corkill JE, Komolafe AJ, Neal TJ, et al. Molecular epidemiology of endemic ciprofloxacin-resistant Neisseria gonorrhoeae in Liverpool. Int J STD AIDS 2003;14:379-85.
5. Aplasca De Los Reyes MR, Pato-Mesola V, Klausner JD, et al. A randomized trial of ciprofloxacin versus cefixime for treatment of gonorrhea after rapid emergence of gonococcal ciprofloxacin resistance in The Philippines. Clin Infect Dis 2001;32:1313-18.
6. Habib AR, Fernando R. Efficacy of azithromycin 1 g single dose in the management of uncomplicated gonorrhoea. Int J STD AIDS 2004;15:240-2.
7. Young H, Moyes A, McMillan A. Azithromycin and erythromycin resistant Neisseria gonorrhoeae following treatment with azithromycin. Int J STD AIDS 1997;8:299-302.
8. Mouton JW. Impact of pharmacodynamics on breakpoint selection for susceptibility testing. Infect Dis Clin N Am 2003;17:579-98.
9. Wiedemann B, Grimm H. Susceptibility to antibiotics: species incidence and trends. In: Lorian V, ed. Antibiotics in laboratory medicine. Baltimore: Williams & Wilkins, 2004:900-1168.
10. Rice RJ, Knapp JS. Antimicrobial susceptibilities of Neisseria gonorrhoeae strains representing five distinct resistance phenotypes. Antimicrob Agents Chemother 1994;38:155-8.
11. James NC, Donn KH, Collins JJ, et al. Pharmacokinetics of cefuroxime axetil and cefoclor: relationship of concentrations in serum to MICs for common respiratory pathogens. Antimicrob Agents Chemother 1991;35:1860-3.
12. Sommers DK, Van Wyk M, et al. Pharmacokinetics and tolerance of cefuroxime axetil in volunteers during repeated dosing. Antimicrob Agents Chemother 1984;25:344-7.
13. Smith BR, LeFrock JL. Cefuroxime: antimicrobial activity, pharmacology, and clinical efficacy. Ther Drug Monit 1983;5:149-60.
14. Yuk JH, Nightingale CH, Quintiliani R. Clinical pharmacokinetics of ceftriaxone. Clin Pharmacokin 1989;17:223-35.
15. Meyers BR, Srulevitch ES, Jocobson J, et al. Crossover study of the pharmacokinetics of ceftriaxone administered intravenously or intramuscularly to healthy volunteers. Antimicrob Agents Chemother 1983;24:812-14.
16. Faulkner RD, Fernandez P, Lawrence G, et al. Absolute bioavailability of cefixime in man. J Clin Pharmacol 1988;28:700-6.
17. Portilla I, Lutz B, Montalvo M, et al. Oral cefixime versus intramuscular ceftriaxone in patients with uncomplicated gonococcal infections. Sex Transm Dis 1992;19:94-8.
18. Price JD, Fluker JL. The efficacy of cefuroxime for the treatment of acute gonorrhoea in men. Br J Vener Dis 1978;54:165-7.
19. Reichman RC, Nolte FS, Wolinsky SM, et al. Single-dose cefuroxime axetil in the treatment of uncomplicated gonorrhea: a controlled trial. Sex Transm Dis 1985;12:184-7.
20. Thorpe EM, Schwebke JR, Hook EW, et al. Comparison of single-dose cefuroxime axetil with ciprofloxacin in treatment of uncomplicated gonorrhea caused by penicillinase-producing and non-penicillinase-producing Neisseria gonorrhoeae strains. Antimicrob Agents Chemother 1996;40:2775-80.
21. Jaffe HW, Schroeter AL, Reynolds GH, et al. Pharmacokinetic determinants of penicillin cure of gonococcal urethritis. Antimicrob Agents Chemother 1979;15:587-91.
22. De Hoop D, Nayyar KC, van Klingeren B, et al. Infections with non-penicillinase-producing Neisseria gonorrhoeae treated with cefuroxime: treatment failures. Sex Transm Dis 1982;9:200-1.